GlassScriptPhysician profile
Jacob Robert Smith
NPI 1326793167
$5,644.19
in general payments reported to CMS, 2019-2025
50 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $490 · 2023: $1,677 · 2024: $1,753 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,154.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.45 | 2023-2025 | |
| Pfizer INC. | $579.21 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $474.50 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $437.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $425.86 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Qol Medical, LLC | $310.56 | 2023-2025 | Sucraid, Sucraid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.86 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $212.91 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $165.83 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $162.22 | 2024 | Nexletol, Nexlizet |
| Axsome Therapeutics, INC. | $141.85 | 2022-2024 | Auvelity |
| Glaxosmithkline, LLC. | $135.16 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $124.43 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.26 | 2022-2023 | |
| Ardelyx, INC. | $105.10 | 2025 | Ibsrela |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.76 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Shield Therapeutics INC | $73.33 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $68.09 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $58.02 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $57.46 | 2025 | Fanapt, Hetlioz |
| Abbott Laboratories | $54.07 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $49.43 | 2023-2025 | Evenity, Repatha, Otezla |
| Daiichi Sankyo INC. | $47.27 | 2023-2025 | Injectafer |
| Idorsia Pharmaceuticals US INC | $45.94 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $42.36 | 2023-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $37.52 | 2022-2023 | Xarelto |
| Collegium Pharmaceutical, INC. | $35.43 | 2024 | Belbuca, Xtampza |
| Sumitomo Pharma America, INC. | $33.99 | 2024-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $32.62 | 2023 | Linzess |
| Protega Pharmaceutials INC | $32.18 | 2025 | Roxybond |
| Antares Pharma, INC. | $32.11 | 2024-2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $31.78 | 2024 | Eliquis |
| Exact Sciences Corporation | $31.71 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ibsa Pharma INC. | $31.63 | 2022-2023 | Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $30.99 | 2024-2025 | Voquezna |
| Lundbeck LLC | $30.32 | 2025 | Rexulti |
| Tris Pharma INC | $29.14 | 2025 | Dyanavel Xr, Onyda Xr |
| Dexcom, INC. | $27.44 | 2022 | |
| Radius Health, INC. | $25.71 | 2025 | Tymlos |
| Bioventus LLC | $24.60 | 2025 | Durolane |
| Lexicon Pharmaceuticals, INC. | $23.73 | 2024 | |
| Boston Scientific Corporation | $23.66 | 2023 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $20.52 | 2025 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $18.92 | 2023 | Trintellix |
| Acella Pharmaceuticals, LLC | $18.39 | 2024 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.25 | 2022 | |
| Grt US Holding, INC. | $15.94 | 2022 | |
| Eisai INC. | $15.00 | 2025 | |
| Cequr Corporation | $6.41 | 2023-2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.